莱美药业(300006.SZ)发布前三季度业绩，归母净亏损4591.72万元

Core Viewpoint - Laimei Pharmaceutical (300006.SZ) reported a decline in revenue and an increase in net loss for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company's operating revenue for the first three quarters was 581 million yuan, representing a year-on-year decrease of 4.06% [1] - The net loss attributable to shareholders of the listed company was 45.9172 million yuan [1] - The net loss attributable to shareholders, excluding non-recurring gains and losses, was 48.379 million yuan [1] - The basic loss per share was 0.0435 yuan [1]